J&J multiple myeloma med wins first nod
To view this email as a web page, click here

Featured Story

Amazon Care is shutting down at the end of 2022. Here's why

Three years after it began piloting a primary care service for its employees that blended telehealth and in-person medical services, Amazon plans to shutter its Amazon Care service for employers.

read more

Top Stories

In new editorial, FDA's Califf says biomedical field should prioritize chronic illness, addiction

FDA Commissioner Robert Califf says the biopharma industry and researchers should redouble its efforts to treat common chronic diseases and addiction. His comments came in a new editorial published in Science.

read more

J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering

Johnson & Johnson and partner Legend Biotech already sell BCMA-targeted CAR-T therapy Carvykti. Now, the company has complemented that complex therapy with an off-the-shelf option.

read more

Fitbit debuts afib detection in health-tracking smartwatch

Just a few months after Fitbit roped in FDA clearance for an algorithm that could be embedded into its eponymous health-tracking wearables to detect atrial fibrillation, the technology is ready to hit the ground running.

read more

UPDATED: PACT Pharma to cull lead asset, divert 54 employees to new business development venture

More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named.

read more

Approval, check. Now, can BioMarin make a commercial success of its hemophilia A gene therapy in Europe?

The European Commission gave Roctavian the all-clear, granting conditional marketing authorization to the med in adults with severe hemophilia A who don’t have factor VIII inhibitors.

read more

Employers concerned about long-term mental health issues post-COVID: survey

Employers view long-term mental health as the key healthcare issue coming out of COVID-19, according to a new survey.

read more

Brain Scientific's EEG headset caps off regulatory push with European approval

With a device that’s now been cleared in both the U.S. and Europe, preparing a patient for an EEG test is almost as easy as strapping on a bike helmet.

read more

Chasing GSK, Pfizer races to regulators after RSV vaccine paints positive impression in RENOIR phase 3

Pfizer has kept up the heat on GSK in the respiratory syncytial virus (RSV) vaccine race, joining its rival in posting positive phase 3 data and staying tucked in its slipstream with plans to seek approval in the fall.

read more

Intermountain Healthcare posts $2.7B profit thanks to SCL Health merger

A $1.7 billion loss from investments would have dragged Intermountain well into the red were it not for more than $4.1 billion in affiliation contributions resulting from the merger deal.

read more

It's a spinoff: Novartis parts ways with Sandoz just as its generics biz shows signs of recovery

Less than a year into a strategic review, Novartis has decided to spin off its generics unit Sandoz. The separation will allow both companies to pursue different capital allocation strategies, CEO Vas Narasimhan, M.D., said.

read more

Aktis makes waves with $84M extension as 3 big pharmas channel funds to radiopharmaceutical pipeline

Aktis Oncology has closed a series A extension round to the tune of $84 million, with big pharmas Merck Novartis and BMS joining to expand the biotech’s bandwidth for developing radiopharmaceutical cancer treatments.

read more

Resources

Whitepaper: Make the most out of hybrid conferences

Improve your congress competitive intelligence and cut down costs by 50%

Whitepaper: Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Whitepaper: The Hands-Free, Low-Volume, Microfluidic Elisa Alternative

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Whitepaper: Plan for scalable process liquid and buffer preparation

Set a solid foundation for successful scale-up of buffer preparation.

Whitepaper: End-to-end support for your asset's commercialization

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

Whitepaper: Genetic Insights for Biopharmaceuticals

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Article: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Case Study: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Article: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

eBook: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Whitepaper: Catalent Pulmonary & Nasal Delivery Capabilities Sheet

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

On-Demand Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.